The European Commission has given Takeda Pharmaceutical Co. Ltd. Permission to market a combination drug for type 2 diabetes in Europe.
The drug, known as Tandemact, is a fixed combination Actos and Glimepiride HC1 tablet. The treatment effectively works in two ways: it targets bodily insulin resistance and also increases the amount of insulin found within the pancreas.
Takeda pharmaceuticals started to sell the product throughout the United States last year, although it was marketed under the name duetact. The company apparently has no plans to introduce the drug into the Japanese market, where combination drugs are less likely to receive approval.
Actos has been extremely successful for Takeda, with sales of the drug continuing to climb year on year. Changes to the American Medicare system have helped to boost sales of the drug.
The news should be warmly recieved by healthcare experts and diabetics alike.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…